Gentian Violet (CID 11057) - BioAssay Data Summary for Compound
.
BioActivity Outcomes:
Active(454)
 
 
Inactive(103)
 
 
Inconclusive(96)
 
 
Unspecified(201)
 
 
Top Targets:
7TM GPCR Srx(12)
 
 
 
p450(12)
 
 
 
 
 
7TM GPCR Srsx(10)
 
 
 
NR LBD PPAR(10)
 
 
 
 
NR LBD TR(10)
 
 
 
 
BioAssay Types:
Confirmatory(320)
 
 
 
 
Literature(151)
 
 
 
 
 
Screening(6)
 
 
 
BioActivity Types:
Potency(224)
 
 
 
 
IC50(124)
 
 
 
EC50(2)
 
 
SAR
Target summary
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 538    Data Row: 854   Total Pages: 18   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID103254526]
EC50 0.02213NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay [AID449703, Type: other]
View
2
[SID17389869]
Potency 0.15Beta amyloid ThS binding assay [AID956, Type: confirmatory]beta-amyloid peptide, A beta {N-terminal} [human, cerebrospinal fluid, conditioned medium of mixed-b [gi:257056]
View
3
[SID17389869]
Potency 0.151461Alpha-synuclein ThS binding assay [AID937, Type: confirmatory]alpha synuclein [Homo sapiens] [gi:46242542]
View
4
[SID17389869]
Potency 0.151461Alpha-synuclein ThS binding assay [AID937, Type: confirmatory]alpha synuclein [Homo sapiens] [gi:46242542]
View
5
[SID103254526]
EC50 0.1703NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay [AID449704, Type: other]
View
6
[SID17389869]
Potency 0.18Tau ThS binding assay [AID911, Type: confirmatory]Microtubule-associated protein tau [Homo sapiens] [gi:92096784]
View
7
[SID17389869]
Potency 0.18Tau ThS binding assay [AID911, Type: confirmatory]Microtubule-associated protein tau [Homo sapiens] [gi:92096784]
View
8
[SID26752909]
Potency 0.1901Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation [AID504834, Type: confirmatory]
View
9
[SID26748060]
Potency 0.2311qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT [AID686979, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
10
[SID26748060]
Potency 0.2311qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT [AID686979, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
11
[SID26748060]
Potency 0.2311qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT [AID686979, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
12
[SID144204635]
Potency 0.2661qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT [AID686978, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
13
[SID144204635]
Potency 0.2661qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT [AID686978, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
14
[SID144204635]
Potency 0.2661qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT [AID686978, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
15
[SID144204635]
Potency 0.2661qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT [AID686979, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
16
[SID144204635]
Potency 0.2661qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT [AID686979, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
17
[SID144204635]
Potency 0.2661qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT [AID686979, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
18
[SID26752909]
Potency 0.3013Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation [AID504832, Type: confirmatory]
View
19
[SID103254526]
IC50 0.46DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin) [AID625225, Type: other]
View
20
[SID103254526]
IC50 0.473DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr)) [AID625184, Type: other]Epidermal growth factor receptor [gi:2811086]
View
21
[SID103254526]
IC50 0.473DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr)) [AID625184, Type: other]Epidermal growth factor receptor [gi:2811086]
View
22
[SID103254526]
IC50 0.473DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr)) [AID625184, Type: other]Epidermal growth factor receptor [gi:2811086]
View
23
[SID26748060]
Potency 0.5174qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT [AID686978, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
24
[SID26748060]
Potency 0.5174qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT [AID686978, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
25
[SID26748060]
Potency 0.5174qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT [AID686978, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
26
[SID103254526]
IC50 0.535DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine) [AID625155, Type: other]Muscarinic acetylcholine receptor M [gi:543761]
View
27
[SID103254526]
IC50 0.535DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine) [AID625155, Type: other]Muscarinic acetylcholine receptor M [gi:543761]
View
28
[SID103254526]
IC50 0.535DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine) [AID625155, Type: other]Muscarinic acetylcholine receptor M [gi:543761]
View
29
[SID103254526]
IC50 0.535DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine) [AID625155, Type: other]Muscarinic acetylcholine receptor M [gi:543761]
View
30
[SID103254526]
IC50 0.536DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912) [AID625201, Type: other]Alpha-2A adrenergic receptor [gi:1351829]
View
31
[SID103254526]
IC50 0.536DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912) [AID625201, Type: other]Alpha-2A adrenergic receptor [gi:1351829]
View
32
[SID17389869]
Potency 0.6682qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay [AID651754, Type: confirmatory]
View
33
[SID17389869]
2nd Test Concentration 0.72Tau Fibrillization assay [AID991, Type: confirmatory]Microtubule-associated protein tau [Homo sapiens] [gi:92096784]
View
34
[SID17389869]
2nd Test Concentration 0.72Tau Fibrillization assay [AID991, Type: confirmatory]Microtubule-associated protein tau [Homo sapiens] [gi:92096784]
View
35
[SID17389869]
Potency 0.7943Cell Viability - LYMP2-022 [AID987, Type: confirmatory]
View
36
[SID103254526]
IC50 0.8244DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) [AID625249, Type: other]Cytochrome P450 2D6 [gi:84028191]
View
37
[SID103254526]
IC50 0.8244DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) [AID625249, Type: other]Cytochrome P450 2D6 [gi:84028191]
View
38
[SID103254526]
IC50 0.831DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone) [AID625254, Type: other]D(3) dopamine receptor [gi:1169206]
View
39
[SID103254526]
IC50 0.831DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone) [AID625254, Type: other]D(3) dopamine receptor [gi:1169206]
View
40
[SID103254526]
IC50 0.831DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone) [AID625254, Type: other]D(3) dopamine receptor [gi:1169206]
View
41
[SID103254526]
IC50 0.831DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone) [AID625254, Type: other]D(3) dopamine receptor [gi:1169206]
View
42
[SID17389869]
Potency 1Cell Viability - LYMP2-012 [AID982, Type: confirmatory]
View
43
[SID103254526]
IC50 1.005DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine) [AID625154, Type: other]Muscarinic acetylcholine receptor M [gi:23503039]
View
44
[SID103254526]
IC50 1.005DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine) [AID625154, Type: other]Muscarinic acetylcholine receptor M [gi:23503039]
View
45
[SID103254526]
IC50 1.005DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine) [AID625154, Type: other]Muscarinic acetylcholine receptor M [gi:23503039]
View
46
[SID103254526]
IC50 1.095DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine) [AID625151, Type: other]Muscarinic acetylcholine receptor M [gi:113118]
View
47
[SID103254526]
IC50 1.095DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine) [AID625151, Type: other]Muscarinic acetylcholine receptor M [gi:113118]
View
48
[SID17389869]
Potency 1.122qHTS for inhibitors of ROR gamma transcriptional activity [AID2551, Type: confirmatory]nuclear receptor ROR-gamma [Mus musculus] [gi:188536040]
View
49
[SID103254526]
IC50 1.155DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine) [AID625270, Type: other]Histamine H2 receptor [gi:123120]
View
50
[SID103254526]
IC50 1.155DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine) [AID625270, Type: other]Histamine H2 receptor [gi:123120]
View